HSA Essential Principles Checklist under GN-16 R4

1. Key takeaways

Singapore requires the applicant to demonstrate that a medical device satisfies the Essential Principles for Safety and Performance under the Health Products (Medical Devices) Regulations 2010, and to explain in checklist form, principle by principle, how conformity is achieved. The governing guidance is GN-16 R4, Guidance on Essential Principles for Safety and Performance of Medical Devices, issued in September 2023, supported by two checklist templates: Annex 2 in the June 2018 version and Annex 3 in the December 2017 version. The checklist is a self-declaratory document, but every entry has to point to evidence that a reviewer can actually open.

• GN-16 R4 of September 2023 is the current revision. Earlier revisions should not be used, even where an existing technical file was built against them.
• Two templates exist side by side, Annex 2 (June 2018) and Annex 3 (December 2017). The choice depends on the basis of the product submission and must be fixed at project kick-off.
• The checklist works as an evidence index rather than a tick-box table. Each line needs a conformity conclusion, the method or standard relied on, and the location of the supporting evidence.
• Principles that do not apply must be marked not applicable with a written reason. A blank line is read the same way as a missing principle.
• The checklist and the ISO 14971 risk management file must corroborate each other, and the checklist becomes the baseline against which later product changes are assessed.

2. Legal basis

The Essential Principles are statutory requirements, not guidance-level suggestions. They sit under the Health Products (Medical Devices) Regulations 2010, and GN-16 R4 explains how an applicant demonstrates conformity with them in a registration submission. The checklist is the vehicle: it converts a set of legal obligations into a structured statement that a reviewer can audit line by line. Because the checklist is declaratory, its value depends entirely on the traceability of what it asserts. A statement of conformity without a locatable evidence reference is, in review terms, an unsupported claim.

In the dossier the checklist occupies a single module, but its reach is wider than that. The verification reports, the labelling samples, the sterilisation validation and the clinical evaluation are all cited from inside it, which means the checklist is effectively an index to the technical file as a whole. When the checklist is written last, as a formality after the technical work is complete, the citations tend to be approximate and the weaknesses become visible at review rather than before submission. Regulatory information in this article was verified to 26 October 2026 against secondary sources, namely GN-16 R4 with its annexes and the GN-17 R5 / GN-18 R5 submission guidance.

3. Expert insights

The checklist is an evidence index, not a tick-box table. The most common error we see in client files is a column of entries reading simply conforming, or yes, followed by nothing. Submissions built that way usually come back with a deficiency request. The workable structure has three columns: the conformity conclusion, the method or standard adopted, and the location of the evidence within the submission, expressed as section number plus document number. HSA reviewers use this table to navigate to the evidence, so the table decides how efficiently the review proceeds. A reviewer who cannot navigate will ask, and every question costs calendar time.

Two template versions are published, and the choice depends on the submission basis. GN-16 R4 supplies both Annex 2 in the June 2018 version and Annex 3 in the December 2017 version. The applicable template has to be confirmed when the project starts, because the templates are structured differently enough that a mid-project switch forces the entire document set to be re-laid out. We record the chosen template and its date in the project file alongside the guidance revision, so that the decision is auditable later.

Not applicable entries require a reason. Not every Essential Principle applies to every product; clauses dealing with active devices, sterilisation or measurement functions are the obvious examples. For those items the checklist cannot simply be left blank. The entry must state that the principle is not applicable and explain why. A blank is treated the same as an omission, and the practical consequence is identical: the reviewer cannot tell whether the applicant considered the principle and excluded it, or never considered it at all.

The Essential Principles and the risk management file must corroborate each other. Most of the answers in the checklist lean on the risk management documentation prepared under ISO 14971. In file review we run one specific test: three Essential Principles are selected at random and traced backwards into the corresponding entries in the risk management report. If the trace fails, the two documents were written separately, and the gap tends to surface as a question the applicant cannot answer cleanly during review.

The checklist is the baseline for later changes. Once a product changes, the Essential Principles assessment has to be re-evaluated, not merely re-dated. We hold the checklist in the standard set of items examined in every change impact assessment, so that a design change, a material substitution or a labelling revision triggers a documented re-assessment rather than an assumption that the original conclusion still holds.

4. Practical recommendations

• Adopt the three-column format of conclusion, method and evidence location, and refuse entries that consist of a bare affirmative with no reference behind it.
• Lock the template version, Annex 2 or Annex 3, at project kick-off and record it in the project file together with the guidance revision.
• Write a reason for every not applicable entry, and neither delete the line nor leave it empty.
• Cross-index the checklist with the ISO 14971 risk management file, then run a reverse trace on three randomly selected principles before submission.
• Include the checklist in the change impact assessment, so that any change passes through the Essential Principles once before it reaches the dossier.

5. Verification checklist

• □ Confirmed that GN-16 R4 is the revision applied, with the matching template version.
• □ Every line carries three columns: conclusion, method and evidence location.
• □ Not applicable entries state a written reason.
• □ Checklist cross-indexed against the ISO 14971 risk management documentation.
• □ Reverse trace test completed, with three sampled principles tracing to identifiable evidence.
• □ Checklist registered as a standard item in the change impact assessment.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com